XBiotech Inc Cash Flow Conversion Efficiency
XBiotech Inc cash flow conversion efficiency. Based on the latest financial reports, XBiotech Inc (XBIT) has a cash flow conversion efficiency ratio of -0.164x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.95 Million) by net assets ($140.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of XBiotech Inc (2012–2025)
Cash flow conversion efficiency of XBiotech Inc from 2012 to 2025. This chart illustrates how XBiotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XBiotech Inc share price for real-time trading data and today's change.
XBiotech Inc Cash Flow Conversion Ratio Explained
XBiotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
XBiotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XBiotech Inc ranked by their cash flow conversion efficiency. Also see XBiotech Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quartiers Properties AB (publ)
ST:QUART-PREF
|
0.048x |
|
Cross Timbers Royalty Trust
NYSE:CRT
|
1.984x |
|
Talaad Thai Leasehold Property Fund
BK:TTLPF
|
0.039x |
|
First Seacoast Bancorp
NASDAQ:FSEA
|
0.010x |
|
Bathurst Resources Ltd
AU:BRL
|
0.011x |
|
Nan Ren Hu Leisure Amusement Co Ltd
TWO:5905
|
0.273x |
|
Mercury Securities Group Berhad
KLSE:0285
|
0.012x |
|
Samchem Holdings Bhd
KLSE:5147
|
0.099x |
Annual Cash Flow Conversion Efficiency for XBiotech Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of XBiotech Inc from 2012 to 2025. Review XBiotech Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $140.35 Million | $-39.92 Million | -0.284x | -67.43% |
| 2024-12-31 | $182.27 Million | $-30.96 Million | -0.170x | -98.54% |
| 2023-12-31 | $218.85 Million | $-18.73 Million | -0.086x | -38.76% |
| 2022-12-31 | $240.40 Million | $-14.82 Million | -0.062x | -123.92% |
| 2021-12-31 | $269.38 Million | $69.44 Million | 0.258x | +237.95% |
| 2020-12-31 | $348.64 Million | $-65.15 Million | -0.187x | -672.86% |
| 2019-12-31 | $755.63 Million | $-18.27 Million | -0.024x | +93.95% |
| 2018-12-31 | $41.40 Million | $-16.54 Million | -0.399x | +28.58% |
| 2017-12-31 | $60.16 Million | $-33.65 Million | -0.559x | +28.21% |
| 2016-12-31 | $59.06 Million | $-46.02 Million | -0.779x | -141.03% |
| 2015-12-31 | $103.05 Million | $-33.31 Million | -0.323x | -63.08% |
| 2014-12-31 | $59.03 Million | $-11.70 Million | -0.198x | +77.24% |
| 2013-12-31 | $10.23 Million | $-8.91 Million | -0.871x | +44.81% |
| 2012-12-31 | $7.37 Million | $-11.63 Million | -1.578x | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more